Characteristics of patients with EGFR-TKIs NSCLC.
收藏数据链接：
官方服务：
资源简介：
Characteristics of patients with EGFR-TKIs NSCLC.
应用场景：
创建时间：
2017-02-04
相关数据集
Data_Sheet_2_Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells.pdf
Background: Lung cancer is the leading cause of cancer death worldwide. More effective treatments are needed to increase durable responses and prolong patient survival. Standard of care treatment for
NIAID Data Ecosystem20
Themes, subthemes and representative quotes of medication experience of patients with non-small cell lung cancer using oral targeted therapy.
Themes, subthemes and representative quotes of medication experience of patients with non-small cell lung cancer using oral targeted therapy.
Figshare2023-05-30 更新10
Data Sheet 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.zip
IntroductionTumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyros
NIAID Data Ecosystem00
DataSheet13_Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.zip
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. Howeve
NIAID Data Ecosystem20
Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis.doc
BackgroundCombining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/
NIAID Data Ecosystem00
